DK1362047T3 - Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer - Google Patents

Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer

Info

Publication number: DK1362047T3
Authority: DK; Denmark
Prior art keywords: indazolyl; kinase inhibitors; kinase; substituted pyrroline; compounds
Prior art date: 2000-12-08

Application number

DK01990971T

Other languages

English (en)

Inventor

Bruce Maryanoff

Han-Cheng Zhang

Bruce Conway

Kimberly White

Hong Ye

Leonard R Hecker

David F Mccomsey

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-08

Filing date

2001-12-06

Publication date

2006-09-04

2001-12-06 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2006-09-04 Application granted granted Critical

2006-09-04 Publication of DK1362047T3 publication Critical patent/DK1362047T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Virology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Immunology (AREA)

DK01990971T 2000-12-08 2001-12-06 Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer DK1362047T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25416600P	2000-12-08	2000-12-08

Publications (1)

Publication Number	Publication Date
DK1362047T3 true DK1362047T3 (da)	2006-09-04

Family

ID=22963185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01990971T DK1362047T3 (da)	2000-12-08	2001-12-06	Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer

Country Status (25)

Country	Link
US (4)	US6849643B2 (da)
EP (1)	EP1362047B1 (da)
JP (1)	JP2004515499A (da)
KR (1)	KR20040016828A (da)
CN (1)	CN1230434C (da)
AT (1)	ATE326464T1 (da)
AU (1)	AU2002230727A1 (da)
BR (1)	BR0116468A (da)
CA (1)	CA2431166A1 (da)
CY (1)	CY1106125T1 (da)
CZ (1)	CZ20031594A3 (da)
DE (1)	DE60119790T2 (da)
DK (1)	DK1362047T3 (da)
ES (1)	ES2263681T3 (da)
HU (1)	HUP0303855A3 (da)
IL (1)	IL156339A0 (da)
MX (1)	MXPA03005140A (da)
NO (1)	NO20032625L (da)
NZ (1)	NZ526356A (da)
PL (1)	PL362576A1 (da)
PT (1)	PT1362047E (da)
RU (1)	RU2003117078A (da)
WO (1)	WO2002046183A2 (da)
YU (1)	YU46603A (da)
ZA (1)	ZA200305239B (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1230434C (zh) *	2000-12-08	2005-12-07	奥索-麦克尼尔药品公司	用作激酶抑制剂的吲唑基取代的吡咯啉化合物
WO2003037384A2 (en) *	2001-10-29	2003-05-08	Nektar Therapeutics Al, Corporation	Polymer conjugates of protein kinase c inhibitors
ES2276048T3 (es)	2002-03-05	2007-06-16	Eli Lilly And Company	Derivados de purina como inhibidores de cinasa.
AU2003217596A1 (en)	2002-03-08	2003-09-22	Eli Lilly And Company	Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors
AU2003225295A1 (en) *	2002-05-08	2003-11-11	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
DE60323749D1 (de) *	2002-06-05	2008-11-06	Janssen Pharmaceutica Nv	Substituierte pyrroline als kinase inhibitoren
CA2520590A1 (en) *	2003-03-27	2004-11-04	Janssen Pharmaceutica, N.V.	Substituted pyrroline kinase inhibitors
EA200600032A1 (ru) *	2003-06-13	2006-06-30	Янссен Фармацевтика Н.В.	Замещённые производные индазолил (индолил) малеимида в качестве ингибиторов киназ
EP1646382A4 (en) *	2003-06-30	2010-07-21	Hif Bio Inc	COMPOUNDS, COMPOSITIONS AND METHODS
CA2538999A1 (en) *	2003-09-19	2005-03-31	Children's Hospital Medical Center	Regulation of cardiac contractility and heart failure propensity
AU2004275720B2 (en) *	2003-09-23	2008-04-24	Merck Sharp & Dohme Corp.	Isoquinoline potassium channel inhibitors
AP2007004039A0 (en) *	2004-11-23	2007-06-30	Internat Biotherapeutic Res In	Method of delivery of therapeutic metal ions, alloys and salts
US8017395B2 (en)	2004-12-17	2011-09-13	Lifescan, Inc.	Seeding cells on porous supports
WO2006073363A1 (en)	2005-01-10	2006-07-13	Astrazeneca Ab	Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
SE0500055D0 (sv)	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
JP2008533172A (ja) *	2005-03-17	2008-08-21	ノバルティスアクチエンゲゼルシャフト	チロシン／スレオニンキナーゼ阻害剤、特にＢ−ＲＡＦキナーゼ阻害剤としての、Ｎ−［３−（１−アミノ−５，６，７，８−テトラヒドロ−２，４，４ｂ−トリアザフルオレン−９−イル）−フェニル］ベンズアミド
AU2006255183B2 (en)	2005-06-08	2012-02-02	Centocor, Inc.	A cellular therapy for ocular degeneration
WO2007008514A2 (en) *	2005-07-07	2007-01-18	Georgetown University	Inhibitors of glycogen synthase kinase 3
JP2009510085A (ja) *	2005-09-29	2009-03-12	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	キナーゼインヒビターとしての大型複素環式化合物
US8741643B2 (en)	2006-04-28	2014-06-03	Lifescan, Inc.	Differentiation of pluripotent stem cells to definitive endoderm lineage
WO2007143119A2 (en) *	2006-06-01	2007-12-13	The Board Of Trustees Of The Leland Stanford Junior University	Method of preventing progression of hypertension-induced heart failure with pkc peptides
EP2125683B1 (en)	2006-12-19	2013-10-23	The Board of Trustees of the University of Illinois	3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders
US20090047246A1 (en) *	2007-02-12	2009-02-19	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
US9080145B2 (en)	2007-07-01	2015-07-14	Lifescan Corporation	Single pluripotent stem cell culture
EP2185693B1 (en)	2007-07-31	2019-07-03	Lifescan, Inc.	Differentiation of human embryonic stem cells
ATE523585T1 (de)	2007-11-27	2011-09-15	Lifescan Inc	Differenzierung menschlicher embryonaler stammzellen
CN105886459A (zh)	2008-02-21	2016-08-24	詹森生物科技公司	用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
US8623648B2 (en) *	2008-04-24	2014-01-07	Janssen Biotech, Inc.	Treatment of pluripotent cells
BRPI0914116A2 (pt)	2008-06-30	2019-09-17	Centocor Ortho Biotech Inc	diferenciação de células-tronco pluripotentes
KR101798474B1 (ko)	2008-10-31	2017-11-16	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 췌장 내분비 계통으로의 분화
CN107904201B (zh)	2008-10-31	2021-11-16	詹森生物科技公司	人胚胎干细胞向胰腺内分泌谱系的分化
PL2366022T3 (pl)	2008-11-20	2016-11-30		Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych
CN102307991B (zh)	2008-11-20	2017-08-15	森托科尔奥索生物科技公司	微载体上的多能干细胞培养
EP2456859A4 (en)	2009-07-20	2015-03-18	Janssen Biotech Inc	DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
AU2010276438B2 (en)	2009-07-20	2015-06-11	Janssen Biotech Inc.	Differentiation of human embryonic stem cells
PL2456858T3 (pl)	2009-07-20	2019-01-31	Janssen Biotech, Inc	Różnicowanie ludzkich embrionalnych komórek macierzystych
EP2516626B1 (en)	2009-12-23	2017-05-10	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells
KR101773538B1 (ko)	2009-12-23	2017-08-31	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 분화
CN102791851B (zh)	2010-03-01	2017-07-14	詹森生物科技公司	纯化衍生自多能干细胞的细胞的方法
CN102958927A (zh)	2010-05-12	2013-03-06	Abbvie公司	激酶的吲唑抑制剂
KR101903562B1 (ko)	2010-05-12	2018-10-02	얀센 바이오테크 인코포레이티드	인간 배아 줄기 세포의 분화
MX348537B (es)	2010-08-31	2017-06-07	Janssen Biotech Inc	Diferencia de celulas madre pluripotentes.
MX355077B (es)	2010-08-31	2018-04-03	Janssen Biotech Inc	Diferenciacion de celulas madre embrionarias humanas.
MX355340B (es)	2010-08-31	2018-04-16	Janssen Biotech Inc	Diferenciación de células madre embrionarias humanas.
RU2668798C2 (ru)	2011-12-22	2018-10-02	Янссен Байотек, Инк.	Способы in vitro пошаговой дифференцировки полюрипотентных клеток
SG11201405052RA (en)	2012-03-07	2014-10-30	Janssen Biotech Inc	Defined media for expansion and maintenance of pluripotent stem cells
EP3450542B1 (en)	2012-06-08	2021-09-01	Janssen Biotech, Inc.	Differentiation of human embryonic stem cells into pancreatic endocrine cells
US9724331B2 (en)	2012-12-10	2017-08-08	Centogene Ag	Use of maleimide derivatives for preventing and treating leukemia
AU2013370228B2 (en)	2012-12-31	2018-10-18	Janssen Biotech, Inc.	Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
MX2015008578A (es)	2012-12-31	2015-09-07	Janssen Biotech Inc	Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
US10370644B2 (en)	2012-12-31	2019-08-06	Janssen Biotech, Inc.	Method for making human pluripotent suspension cultures and cells derived therefrom
AU2013368221B2 (en)	2012-12-31	2018-11-01	Janssen Biotech, Inc.	Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
MX2016015004A (es)	2014-05-16	2017-06-27	Janssen Biotech Inc	Uso de moleculas pequeñas para mejorar la expresion de mafa en celulas endocrinas pancreaticas.
GB201509885D0 (en) *	2015-06-08	2015-07-22	Ucb Biopharma Sprl	Therapeutic agents
MA45479A (fr)	2016-04-14	2019-02-20	Janssen Biotech Inc	Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
SG10201910821XA (en)	2016-12-30	2020-01-30	Frequency Therapeutics Inc	1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US10383881B2 (en)	2016-12-30	2019-08-20	Frequency Therapeutics, Inc.	1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
IL316875A (en)	2018-10-05	2025-01-01	Annapurna Bio Inc	Compounds and compositions for treating conditions associated with APJ receptor activity
US20220133740A1 (en)	2019-02-08	2022-05-05	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
HUE068174T2 (hu)	2020-02-07	2024-12-28	Gasherbrum Bio Inc	Heterociklusos GLP-1 agonisták
CN120957993A (zh)	2023-02-16	2025-11-14	加舒布鲁姆生物公司	杂环glp-1激动剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK75289A3 (en) *	1988-02-10	1998-05-06	Hoffmann La Roche	Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8904161D0 (en) *	1989-02-23	1989-04-05	Hoffmann La Roche	Substituted pyrroles
MC2096A1 (fr)	1989-02-23	1991-02-15	Hoffmann La Roche	Pyrroles substitues
DE4005969A1 (de)	1990-02-26	1991-08-29	Boehringer Mannheim Gmbh	Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de)	1990-02-26	1991-08-29	Boehringer Mannheim Gmbh	Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5624949A (en)	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
EP1449529B1 (en)	1993-12-23	2010-01-27	Eli Lilly And Company	Protein Kinase C Inhibitors
SE9603283D0 (sv)	1996-09-10	1996-09-10	Astra Ab	New compounds
EP1057484A4 (en)	1998-02-23	2002-11-20	Sagami Chem Res	INHIBITORS OF CELL DEATH
CA2338866A1 (en)	1998-07-30	2000-02-10	Japan Tobacco Inc.	Disubstituted maleimide compound and pharmaceutical use thereof
AU6111699A (en)	1998-10-08	2000-05-01	Smithkline Beecham Plc	Novel method and compounds
CN1230434C (zh) *	2000-12-08	2005-12-07	奥索-麦克尼尔药品公司	用作激酶抑制剂的吲唑基取代的吡咯啉化合物
AU2003225295A1 (en)	2002-05-08	2003-11-11	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
KR20050008787A (ko)	2002-06-05	2005-01-21	얀센 파마슈티카 엔.브이.	키나제 저해제로서의 비스인돌릴-말레이미드 유도체
DE60323749D1 (de)	2002-06-05	2008-11-06	Janssen Pharmaceutica Nv	Substituierte pyrroline als kinase inhibitoren
CA2520590A1 (en)	2003-03-27	2004-11-04	Janssen Pharmaceutica, N.V.	Substituted pyrroline kinase inhibitors
EA200600032A1 (ru) *	2003-06-13	2006-06-30	Янссен Фармацевтика Н.В.	Замещённые производные индазолил (индолил) малеимида в качестве ингибиторов киназ

2001
- 2001-12-06 CN CNB018225675A patent/CN1230434C/zh not_active Expired - Fee Related
- 2001-12-06 ES ES01990971T patent/ES2263681T3/es not_active Expired - Lifetime
- 2001-12-06 CA CA002431166A patent/CA2431166A1/en not_active Abandoned
- 2001-12-06 BR BR0116468-6A patent/BR0116468A/pt not_active IP Right Cessation
- 2001-12-06 KR KR10-2003-7007710A patent/KR20040016828A/ko not_active Ceased
- 2001-12-06 PT PT01990971T patent/PT1362047E/pt unknown
- 2001-12-06 AT AT01990971T patent/ATE326464T1/de not_active IP Right Cessation
- 2001-12-06 DE DE60119790T patent/DE60119790T2/de not_active Expired - Fee Related
- 2001-12-06 DK DK01990971T patent/DK1362047T3/da active
- 2001-12-06 WO PCT/US2001/047689 patent/WO2002046183A2/en not_active Ceased
- 2001-12-06 NZ NZ526356A patent/NZ526356A/xx unknown
- 2001-12-06 PL PL01362576A patent/PL362576A1/xx not_active Application Discontinuation
- 2001-12-06 RU RU2003117078/04A patent/RU2003117078A/ru not_active Application Discontinuation
- 2001-12-06 MX MXPA03005140A patent/MXPA03005140A/es active IP Right Grant
- 2001-12-06 HU HU0303855A patent/HUP0303855A3/hu unknown
- 2001-12-06 YU YU46603A patent/YU46603A/sh unknown
- 2001-12-06 US US10/013,181 patent/US6849643B2/en not_active Expired - Lifetime
- 2001-12-06 AU AU2002230727A patent/AU2002230727A1/en not_active Abandoned
- 2001-12-06 CZ CZ20031594A patent/CZ20031594A3/cs unknown
- 2001-12-06 EP EP01990971A patent/EP1362047B1/en not_active Expired - Lifetime
- 2001-12-06 IL IL15633901A patent/IL156339A0/xx unknown
- 2001-12-06 JP JP2002547921A patent/JP2004515499A/ja not_active Ceased
2003
- 2003-06-10 NO NO20032625A patent/NO20032625L/no not_active Application Discontinuation
- 2003-07-07 ZA ZA200305239A patent/ZA200305239B/en unknown
2004
- 2004-07-06 US US10/885,373 patent/US7304060B2/en not_active Expired - Fee Related
- 2004-08-02 US US10/909,537 patent/US7329657B2/en not_active Expired - Fee Related
2006
- 2006-07-21 CY CY20061101017T patent/CY1106125T1/el unknown
2007
- 2007-12-13 US US12/001,805 patent/US7855203B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE326464T1 (de)	2006-06-15
HUP0303855A3 (en)	2005-04-28
US7855203B2 (en)	2010-12-21
IL156339A0 (en)	2004-01-04
BR0116468A (pt)	2004-06-29
US20040259928A1 (en)	2004-12-23
JP2004515499A (ja)	2004-05-27
US7304060B2 (en)	2007-12-04
RU2003117078A (ru)	2004-12-10
US20050004202A1 (en)	2005-01-06
CA2431166A1 (en)	2002-06-13
CN1489586A (zh)	2004-04-14
CY1106125T1 (el)	2011-06-08
NO20032625D0 (no)	2003-06-10
WO2002046183A2 (en)	2002-06-13
US7329657B2 (en)	2008-02-12
AU2002230727A1 (en)	2002-06-18
PL362576A1 (en)	2004-11-02
US6849643B2 (en)	2005-02-01
PT1362047E (pt)	2006-09-29
HUP0303855A2 (hu)	2004-03-01
WO2002046183A3 (en)	2002-09-06
DE60119790T2 (de)	2007-01-25
YU46603A (sh)	2006-05-25
NZ526356A (en)	2005-02-25
NO20032625L (no)	2003-08-05
DE60119790D1 (de)	2006-06-22
ZA200305239B (en)	2004-10-07
US20080096949A1 (en)	2008-04-24
HK1057370A1 (en)	2004-04-02
KR20040016828A (ko)	2004-02-25
EP1362047A2 (en)	2003-11-19
EP1362047B1 (en)	2006-05-17
CN1230434C (zh)	2005-12-07
ES2263681T3 (es)	2006-12-16
MXPA03005140A (es)	2004-10-15
CZ20031594A3 (cs)	2004-06-16
US20030055097A1 (en)	2003-03-20

Publication	Publication Date	Title
DK1362047T3 (da)	2006-09-04	Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer
DE60323749D1 (de)	2008-11-06	Substituierte pyrroline als kinase inhibitoren
DE60319364D1 (de)	2008-04-10	Substituierte pyrroline als kinase inhibitoren
AU2737102A (en)	2002-06-18	Macroheterocylic compounds useful as kinase inhibitors
BG106585A (en)	2003-03-31	Kinase inhibitors as therapeutic agents
YU84603A (sh)	2006-03-03	Novi inhibitori tirozin kinaze
EA200300906A1 (ru)	2004-02-26	Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
MXPA03011907A (es)	2004-03-26	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
MXPA02005844A (es)	2004-08-12	Inhibidores de cinasas de proteina.
BR0208105A (pt)	2004-03-09	Inibidores de metaloproteinase
BR0308787A (pt)	2005-01-11	Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
EA200401157A1 (ru)	2005-06-30	N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
AU3741801A (en)	2001-09-24	Substituted beta-carbolines with ikb-kinase inhibiting activity
BRPI0412894A (pt)	2006-10-03	tienopiridina e furopiridina inibidores de quinases
EP1534695A4 (en)	2008-06-11	tyrosine kinase inhibitors
WO2004030620A3 (en)	2004-06-10	Novel tyrosine kinase inhibitors
BR0209149A (pt)	2004-07-13	Ftalazinonas
PL371127A1 (en)	2005-06-13	6-aminomorphinane derivatives, method for the production and use thereof
DE60121587D1 (de)	2006-08-31	Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EP1496907A4 (en)	2006-05-10	Tyrosine kinase inhibitor
EP1496898A4 (en)	2006-05-10	Tyrosine kinase inhibitor